|
Aventis and Bayer end negotiations on biologicals joint venture Strasbourg, France January 31, 2003 Aventis and Bayer have agreed not to pursue their plans to create a joint venture in the field of biological products. It had been intended to combine Aventis Behring, the therapeutic proteins business of Aventis, with the Biological Products Division of Bayer HealthCare. Both companies reviewed various possible forms of cooperation. A final agreement on the terms of the transaction could not be reached. Aventis is pro-actively exploring alternative options for the future of Aventis Behring. Aventis is dedicated to improving life by treating and preventing human disease through the discovery and development of innovative prescription drugs for important therapeutic areas as well as human vaccines. In 2001, Aventis generated sales of € 17.7 billion, invested € 3 billion in research and development and employed approximately 75,000 people in its core business. Aventis corporate headquarters are in Strasbourg, France. For more information, please visit: www.aventis.com Statements in this news release other than historical information are forward-looking statement subject to risks and uncertainties. Actual results could differ materially depending on factors such as the availability of resources, the timing and effects of regulatory actions, the strength of competition, the outcome of litigation and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission. Your Contact: Source: |